Rafferty Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $22.9M | Sell |
29,589
-5,730
| -16% | -$4.39M | 0.09% | 119 |
|
|
2025
Q4 | $27.3M | Sell |
35,319
-11,153
| -24% | -$7.57M | 0.09% | 124 |
|
|
2025
Q3 | $26.1M | Sell |
46,472
-6,156
| -12% | -$3.48M | 0.08% | 127 |
|
|
2025
Q2 | $27.6M | Buy |
52,628
+7,926
| +18% | +$4.42M | 0.09% | 115 |
|
|
2025
Q1 | $28.4M | Sell |
44,702
-2,906
| -6% | -$2M | 0.12% | 105 |
|
|
2024
Q4 | $33.9M | Buy |
47,608
+11,909
| +33% | +$9.99M | 0.12% | 105 |
|
|
2024
Q3 | $37.5M | Sell |
35,699
-5,518
| -13% | -$6.14M | 0.13% | 92 |
|
|
2024
Q2 | $43.3M | Buy |
41,217
+7,945
| +24% | +$7.7M | 0.16% | 74 |
|
|
2024
Q1 | $32M | Sell |
33,272
-904
| -3% | -$860K | 0.12% | 96 |
|
|
2023
Q4 | $30M | Buy |
34,176
+2,121
| +7% | +$1.75M | 0.13% | 99 |
|
|
2023
Q3 | $26.4M | Buy |
32,055
+1,411
| +5% | +$1.11M | 0.16% | 90 |
|
|
2023
Q2 | $22M | Buy |
30,644
+4,971
| +19% | +$3.83M | 0.12% | 103 |
|
|
2023
Q1 | $21.1M | Sell |
25,673
-364
| -1% | -$275K | 0.14% | 102 |
|
|
2022
Q4 | $18.8M | Buy |
26,037
+1,245
| +5% | +$919K | 0.16% | 103 |
|
|
2022
Q3 | $17.1M | Buy |
24,792
+4,467
| +22% | +$2.81M | 0.18% | 92 |
|
|
2022
Q2 | $12M | Sell |
20,325
-897
| -4% | -$583K | 0.11% | 112 |
|
|
2022
Q1 | $14.8M | Buy |
21,222
+3,136
| +17% | +$1.98M | 0.09% | 136 |
|
|
2021
Q4 | $11.4M | Buy |
18,086
+3,487
| +24% | +$2.14M | 0.06% | 166 |
|
|
2021
Q3 | $8.84M | Buy |
14,599
+665
| +5% | +$413K | 0.06% | 180 |
|
|
2021
Q2 | $7.78M | Sell |
13,934
-2,691
| -16% | -$1.36M | 0.05% | 224 |
|
|
2021
Q1 | $7.87M | Buy |
16,625
+5,466
| +49% | +$2.66M | 0.05% | 200 |
|
|
2020
Q4 | $5.39M | Buy |
11,159
+497
| +5% | +$268K | 0.05% | 204 |
|
|
2020
Q3 | $5.97M | Buy |
10,662
+1,708
| +19% | +$1.04M | 0.07% | 162 |
|
|
2020
Q2 | $5.58M | Buy |
8,954
+733
| +9% | +$416K | 0.08% | 155 |
|
|
2020
Q1 | $4.01M | Sell |
8,221
-11,646
| -59% | -$4.8M | 0.17% | 69 |
|
|
2019
Q4 | $7.46M | Sell |
19,867
-10,489
| -35% | -$3.53M | 0.11% | 102 |
|
|
2019
Q3 | $8.42M | Buy |
30,356
+6,157
| +25% | +$1.82M | 0.13% | 86 |
|
|
2019
Q2 | $7.57M | Buy |
24,199
+6,710
| +38% | +$2.23M | 0.13% | 94 |
|
|
2019
Q1 | $7.18M | Buy |
17,489
+12,926
| +283% | +$5.32M | 0.12% | 94 |
|
|
2018
Q4 | $1.7M | Sell |
4,563
-801
| -15% | -$293K | 0.04% | 241 |
|
|
2018
Q3 | $2.17M | Sell |
5,364
-40
| -0.7% | -$15.2K | 0.03% | 271 |
|
|
2018
Q2 | $1.86M | Buy |
5,404
+431
| +9% | +$135K | 0.03% | 308 |
|
|
2018
Q1 | $1.71M | Buy |
4,973
+1,186
| +31% | +$413K | 0.03% | 325 |
|
|
2017
Q4 | $1.42M | Sell |
3,787
-1,332
| -26% | -$539K | 0.02% | 364 |
|
|
2017
Q3 | $2.29M | Buy |
5,119
+2,008
| +65% | +$955K | 0.05% | 203 |
|
|
2017
Q2 | $1.53M | Buy |
3,111
+87
| +3% | +$38.1K | 0.04% | 250 |
|
|
2017
Q1 | $1.17M | Buy |
3,024
+366
| +14% | +$136K | 0.03% | 285 |
|
|
2016
Q4 | $976K | Buy |
2,658
+861
| +48% | +$327K | 0.04% | 220 |
|
|
2016
Q3 | $722K | Buy |
1,797
+138
| +8% | +$55.4K | 0.03% | 269 |
|
|
2016
Q2 | $579K | Sell |
1,659
-1,679
| -50% | -$647K | 0.04% | 344 |
|
|
2016
Q1 | $1.2M | Sell |
3,338
-848
| -20% | -$349K | 0.07% | 211 |
|
|
2015
Q4 | $2.29M | Buy |
4,186
+269
| +7% | +$146K | 0.28% | 86 |
|
|
2015
Q3 | $1.82M | Buy |
3,917
+259
| +7% | +$139K | 0.14% | 138 |
|
|
2015
Q2 | $1.87M | Buy |
3,658
+1,830
| +100% | +$893K | 0.13% | 125 |
|
|
2015
Q1 | $825K | Buy |
1,828
+274
| +18% | +$116K | 0.06% | 271 |
|
|
2014
Q4 | $638K | Buy |
1,554
+423
| +37% | +$166K | 0.14% | 153 |
|
|
2014
Q3 | $408K | Buy |
1,131
+280
| +33% | +$93.8K | 0.04% | 189 |
|
|
2014
Q2 | $240K | Sell |
851
-490
| -37% | -$145K | 0.05% | 281 |
|
|
2014
Q1 | $403K | Buy |
1,341
+379
| +39% | +$117K | 0.08% | 110 |
|
|
2013
Q4 | $265K | Buy |
+962
| New | +$277K | 0.06% | 210 |
|
Other funds holding REGN
VCM
N
Rafferty Asset Management's REGN Position: Q1 2026 in Review
Rafferty Asset Management reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q1 2026, selling an estimated $4.39M and leaving 29,589 shares worth $22.9M. The position accounts for 0.09% of the portfolio, ranked #119.
Rafferty Asset Management first reported a position in REGN in Q4 2013 and has held it in 50 quarters since. The position peaked at $43.3M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Rafferty Asset Management held 29,589 shares of Regeneron Pharmaceuticals worth $22.9M as of Q1 2026.
- Rafferty Asset Management sold 5,730 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $4.39M.
- Regeneron Pharmaceuticals made up 0.09% of Rafferty Asset Management's portfolio in Q1 2026, its #119 holding.
- Rafferty Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 50 quarters since.
- Rafferty Asset Management's Regeneron Pharmaceuticals position peaked at $43.3M in Q2 2024.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.